Marinus Pharmaceuticals Inc

+0.37 (+2.70%)

Marinus Awarded BARDA Contract To Develop IV Ganaxolone

Published: 09/14/2020 12:41 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Awarded Barda Contract to Develop Iv Ganaxolone for Treatment of Refractory Status Epilepticus Caused by Nerve Agent Exposure.
Marinus Pharmaceuticals Inc - Barda to Fund Up to $51 Million of $84 Million Contract for Programs Related to Refractory Status Epilepticus (rse) Development.
Marinus - 5-year Contract Supports Clinical Development of Iv Ganaxolone for Treatment of Rse, Including Treatment of Individuals Exposed to Nerve Gas.
Marinus Pharmaceuticals - Barda Will Fund Pre-clinical Studies of Iv Ganaxolone Treatment Following Nerve Agent Exposure in Established Animal Models.
Marinus Pharmaceuticals Inc - Under Contract, Co Will Be Responsible for Cost-sharing in Amount of $33 Million If All Development Options Are Completed.